1 / 46

Rosacea

Rosacea. Cause unknown Aggravated by anything giving vasodilatation eg heat or caffeine Usually over 40yrs females, worse in males/Celts Onset gradual with papules and pustules on the cheeks chin mid forehead and tip of nose Erythematous background, often with associated telangiectasia.

ally
Télécharger la présentation

Rosacea

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Rosacea • Cause unknown • Aggravated by anything giving vasodilatation eg heat or caffeine • Usually over 40yrs females, worse in males/Celts • Onset gradual with papules and pustules on the cheeks chin mid forehead and tip of nose • Erythematous background, often with associated telangiectasia

  2. Distribution Papules/pustules/erythema Nasolabial sparing

  3. Rhinophyma

  4. Can be unilateral Subtle telangiectasiae

  5. Opthalmological problems • Up to 5% rosacea patients • Blepharoconjunctivitis • Lid hygeine, oral oxytetracycline for 6 wks if severe • Dry eyes – ocular lubricants • Chronic corneal inflammation and neovascularisation respond to low dose topical steroid (but risk of perforation) • Corneal perforation – keratoplasty

  6. Prominent telangiectasiae suggests topical steroid use • Gross rosacea

  7. Rosacea may persist and worsen • Exacerbated by anything causing flushing • Persistent red face with flushing may prove resistant to treatment • Remember carcinoid, facial fluishing but absence of other stigmata of rosacea.

  8. Treatment • Mainstay broad spec antibiotics, mode of action unknown • Oxytetracycline 500 mgs bd • Rule of 1/3rds • 1/3rd better after 8 wks • 1/3rd better after 2nd or 3rd 8 wks of oxytet • 1/3rd need long term due to persistent relapse on cessation of treatment

  9. Can use erythromycin or doxycycline • Antibiotics given for 2 months, should see improvement by 16 wks • Topicals • 0.75% metronidazole gel (Rosex) not as effective as oral antibiotics • Useful if get a flare of rosacea • Helpful to women candidiasis on antibiotics • Azaleic acid gel 15% • Clindamycin gel

  10. 58 trials, 6633 participants Doxycycline better than placebo 40mgs as effective as 100mgs Topical metronidazole Topical alazaic acid Further well-designed, adequately-powered randomised controlled trials are required Cochrane link

  11. Treatment failure? • Most will have erythema/telangiectasiae ‘red face’ • Telangiectasiae can be treated by laser • Cosmetic camouflage • Referral for • classical rosacea not responding to treatment ?roaccutane • Significant rhinophyma – laser recontouring • Opthalmological rosacea

  12. Seborrhoeic Eczema • Overgrowth of P. ovale (malassesia) in hair follicles giving a secondary eczematous response. • >30 yrs • males > females • Immunocompromised (HIV) • Gradual onset with erythema then scale usually in nasolabial folds • Often have scalp involvement – dandruff

  13. Pink or red scaly ill defined patches, may become more acute with exudates. • Typical distribution • nasolabial folds, • eyebrows, • eyelashes (blepharitis), • ext auditory meatus • Scalp • Chest

  14. Treatment • Tends to be persistent, fluctuating with weather, stress • Need to know how to look after the problem Pityrosporum ovale antifungals Inflammation topical steroids

  15. Treatment • Treat yeast with imidazole eg ketoconazole • Nizoral shampoo twice weekly and cream bd • Maintainance shampoo once every 2 wks and cream in bursts every 2 weeks • 1% Hydrocortisone cream • 2% salicylic acid, 2% sulphur in aq. Cream • Lithium (ethalith) may be effective

  16. SLE • A syndrome • Idiopathic or drug induced associated with autoantibodies • General symptoms • Fatigue • Fever • Weight loss • Malaise

  17. SLE malar rash

  18. Diagnosis: SLE requires 4 of 11 criteria • Malar rash • Discoid rash • Photosensitivity • Oral Ulcers • Polyarthritis involving more than 2 joints • Pleuritis or Pericarditis • Antinuclear antibody titer positive (1:40 or higher) • Titer over 1:320 is very suggestive • Renal disease • Neurologic disorder (e.g. Seizures, Psychosis) • Anaemia, neutropenia or thrombocytopenia • Anti-dsDNA, Anti-Sm positive, syphilis false positive

  19. CDLE • Probably autoimmune affecting skin only not assoc with circulating antibodies • Precipitated and aggravated by sun • Middle aged and above • Gradual onset, patients notice scaly patches on the face • Absence of systemic symptoms

  20. Prognosis, tends to persist until burnt out • Treatment • Potent top steroids – ie dermovate regularly • High factor sunscreens • Antimalarials – hydroxychloroquine if extensive or doesn’t respond • Retinoids • Immunosuppressants if severe and extensive

  21. Light induced problems • Light sensitivity Juvenile Spring Eruption PLE • Sun damaged Solar elastosis AKs • DLE • SLE • Melasma

  22. Actinic keratoses • Malignant potential • 0.1 – 10% • > 40yrs up to 40% population • May regress, remain static or undergo malignant transformation • Cryotherapy • Diclofenac • 5-fluouracil • Imiquimod • PDT

  23. Treatment • Cryotherapy 5-15 secs freeze time • 3% Diclofenac (Solaraze) gel BNF: Apply thinly twice daily for 60–90 days; max. 8 g daily (carry on up the…………) • Imiquimod (Aldara). BNF: apply to lesion 3 times a week for 4 weeks; assess response after a 4 week treatment-free interval; repeat 4-week course if lesions persist; max. 2 courses Local reactions common on this regime – erythema, burning, ulceration, headache, flu symptoms

  24. Field change actinic damage • Imiquimod weekly for 24 wks • 20 patients 28 wk trial once weekly for 24 wks assessed at 28 wks • 46.7% marked improvement • 6.7% improved on placebo • 5-FU (BNF) Apply thinly to the affected area once or twice daily; if possible, cover malignant lesions with occlusive dressing; max. area of skin treated at one time, 500 cm2 (23x23cm); usual duration of initial therapy, 3–4 weeks • Local irritation, severe discomfort (top steroid)

More Related